- New research analyzing 146,000 patient records found GLP-1 users developed osteoporosis at a 29% higher relative risk than nonusers.
- A February 2026 study linked GLP-1 drugs to an 11% higher risk of fragility fractures in older adults.
- Clinical trial data showed semaglutide reduced hip bone density by 2.6% and spine density by 2.1% over 52 weeks.
- Appetite suppression reduces calcium, vitamin D, magnesium and protein intake that bone tissue requires for maintenance.
- Experts recommend resistance exercise, calcium supplementation and protein intake of 1.2-1.6 grams per kilogram daily for users.
More than 1 in 8 Americans now take GLP-1 receptor agonists like Ozempic and Wegovy, watching the number on the scale drop. But new research presented in March 2026 at the American Academy of Orthopaedic Surgeons annual meeting is revealing a pattern that most prescribing physicians are not discussing: these drugs may be quietly destroying bone density at rates that could reshape the health of millions. The five-year analysis of more than 146,000 adults with obesity and type 2 diabetes found that GLP-1 users developed osteoporosis at a 29% higher relative risk compared to nonusers, while the risk of osteomalacia — a condition involving bone softening — more than doubled. A separate February 2026 study in the Journal of Clinical Endocrinology & Metabolism reinforced these findings, showing that older adults on GLP-1 drugs faced an 11% higher risk of fragility fractures compared to those on other diabetes medications.
What the clinical data reveals
The five-year observational findings are supported by randomized controlled trial data that directly measured bone changes. A phase 2 clinical trial found that 52 weeks of once-weekly semaglutide reduced hip bone mineral density by 2.6% compared to placebo. Lumbar spine density dropped by 2.1%. Throughout the trial, bone resorption markers increased while bone formation markers did not compensate — meaning the body was breaking down bone faster than it could rebuild, with no recovery signal while the drug remained active.
These findings align with decades of research on rapid weight loss. Significant weight reduction of roughly 7% to 10% through calorie restriction, with or without exercise, consistently results in high-turnover bone loss. Bariatric surgery produces similar effects. What distinguishes GLP-1 drugs is their widespread use: approximately 12% of Americans currently take these medications, and as many as 35% report interest in using them. Tens of millions of people may be on a trajectory toward accelerated bone loss, with most having received no screening, no guidance on supplementation, and no discussion of how pharmaceutical-driven weight loss affects the skeleton.
Why appetite suppression weakens the skeleton
The mechanism behind bone risk is not mysterious. When appetite drops dramatically, food intake falls, and with that drop goes the calcium, vitamin D, magnesium and protein that bone tissue depends on to maintain density and repair cellular damage. Bone is a dynamic system that continuously breaks down old tissue and rebuilds new tissue. That process requires a steady supply of specific nutrients to stay in balance. When that nutrient supply is cut, breakdown outpaces rebuilding.
Weight loss compounds the problem because bones respond to mechanical load. Lighter bodies place less stress on the skeleton, and the skeleton responds by reducing density. Every pound lost reduces the stimulus that tells bone cells to maintain mass. Dr. Clifford Rosen, a professor of medicine at Tufts University who studies GLP-1 impacts on bone health, noted that the central question is whether this represents a normal skeletal compensation or a more rapid bone loss than expected.
This historical context matters because earlier weight-loss interventions — from fen-phen in the 1990s to the Atkins diet craze — also raised concerns about nutrient depletion. But those regimens affected far fewer people. Never before have 1 in 8 Americans been on medications that simultaneously suppress appetite and drive rapid weight loss, creating a population-scale experiment in bone health with no precedent.
Steps every GLP-1 user should take now
Calcium, vitamin D and protein must become non-negotiable daily priorities for anyone taking GLP-1 medications. Because appetite suppression reduces food intake, users face a real risk of falling below the nutrient thresholds bone maintenance requires. Calcium intake should reach 1,000 to 1,200 milligrams daily. Vitamin D blood levels should sit between 40 and 60 ng/mL — a target most people on standard supplementation do not reach without testing and adjustment. Protein intake of 1.2 to 1.6 grams per kilogram of body weight daily supports both muscle preservation and the collagen matrix that gives bone structural integrity.
Resistance exercise should be treated as a medical intervention, not an optional habit. Mechanical load is one of the most powerful signals the body uses to maintain bone density. Research consistently confirms that resistance exercise preserves bone mineral density during weight loss, and when GLP-1s are combined with structured exercise, bone density loss is largely mitigated. Even two to three sessions per week of bodyweight exercises or light free weights provide significant skeletal protection.
Supplementation beyond calcium alone may be necessary. Magnesium is required for calcium absorption and is frequently depleted alongside vitamin D. Vitamin K2 directs calcium into bone tissue rather than arterial walls. Collagen peptide supplementation has shown positive effects on bone mineral density in clinical trials.
The takeaway is refinement, not fear
The Food and Drug Administration already notes in its label for semaglutide that it may increase fracture risk in older adults and women. But the agency has not mandated warnings for muscle or bone atrophy despite mounting evidence. Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in North Carolina, emphasized that the research should not alter prescribing of GLP-1 medications but should serve as a reminder that obesity treatment also requires guidance on protein intake, exercise and bone health monitoring. His assessment: the takeaway is not fear but refinement.
Five years of data have confirmed what the mechanism always suggested. Drugs that suppress appetite and drive rapid weight loss also reduce the nutritional inputs and mechanical stimuli that bone tissue needs to stay strong. For the millions of Americans currently taking these medications and the millions more considering them, the number on the scale tells only part of the story. What remains unwatched is what is happening to the skeleton beneath.
Sources for this article include:
Please contact us for more information.